Published in J Biol Chem on March 10, 2010
Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. Hum Mol Genet (2011) 2.34
Polyglutamine- and temperature-dependent conformational rigidity in mutant huntingtin revealed by immunoassays and circular dichroism spectroscopy. PLoS One (2014) 1.48
α-Synuclein oligomers and clinical implications for Parkinson disease. Ann Neurol (2012) 1.42
Physical chemistry of polyglutamine: intriguing tales of a monotonous sequence. J Mol Biol (2012) 1.37
Tracking mutant huntingtin aggregation kinetics in cells reveals three major populations that include an invariant oligomer pool. J Biol Chem (2010) 1.28
A genetic screening strategy identifies novel regulators of the proteostasis network. PLoS Genet (2011) 1.19
Slow amyloid nucleation via α-helix-rich oligomeric intermediates in short polyglutamine-containing huntingtin fragments. J Mol Biol (2011) 1.17
Assessing the contribution of heterogeneous distributions of oligomers to aggregation mechanisms of polyglutamine peptides. Biophys Chem (2011) 1.13
Formation and toxicity of soluble polyglutamine oligomers in living cells. PLoS One (2010) 1.12
Identification of novel potentially toxic oligomers formed in vitro from mammalian-derived expanded huntingtin exon-1 protein. J Biol Chem (2012) 1.07
A major role for side-chain polyglutamine hydrogen bonding in irreversible ataxin-3 aggregation. PLoS One (2011) 1.05
In vitro and in vivo aggregation of a fragment of huntingtin protein directly causes free radical production. J Biol Chem (2011) 1.05
A compact beta model of huntingtin toxicity. J Biol Chem (2011) 1.04
Dendritic spine loss and neurodegeneration is rescued by Rab11 in models of Huntington's disease. Cell Death Differ (2010) 1.04
Amyloid in neurodegenerative diseases: friend or foe? Semin Cell Dev Biol (2011) 1.02
Hsp70 and Hsp40 functionally interact with soluble mutant huntingtin oligomers in a classic ATP-dependent reaction cycle. J Biol Chem (2010) 1.01
Biophysical insights into how surfaces, including lipid membranes, modulate protein aggregation related to neurodegeneration. Front Neurol (2013) 0.96
The interaction of polyglutamine peptides with lipid membranes is regulated by flanking sequences associated with huntingtin. J Biol Chem (2013) 0.94
Cellular inclusion bodies of mutant huntingtin exon 1 obscure small fibrillar aggregate species. Sci Rep (2012) 0.94
Exogenous delivery of chaperonin subunit fragment ApiCCT1 modulates mutant Huntingtin cellular phenotypes. Proc Natl Acad Sci U S A (2013) 0.93
PolyQ disease: misfiring of a developmental cell death program? Trends Cell Biol (2012) 0.93
Cysteine oxidation within N-terminal mutant huntingtin promotes oligomerization and delays clearance of soluble protein. J Biol Chem (2011) 0.93
Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models. J Neurosci (2012) 0.92
Detection of Mutant Huntingtin Aggregation Conformers and Modulation of SDS-Soluble Fibrillar Oligomers by Small Molecules. J Huntingtons Dis (2012) 0.89
Protein tau: prime cause of synaptic and neuronal degeneration in Alzheimer's disease. Int J Alzheimers Dis (2012) 0.88
Rab11 rescues synaptic dysfunction and behavioural deficits in a Drosophila model of Huntington's disease. Hum Mol Genet (2012) 0.87
Biophysical underpinnings of the repeat length dependence of polyglutamine amyloid formation. J Biol Chem (2014) 0.87
Aggregation formation in the polyglutamine diseases: protection at a cost? Mol Cells (2013) 0.87
Sequestration of Sup35 by aggregates of huntingtin fragments causes toxicity of [PSI+] yeast. J Biol Chem (2012) 0.86
Role of p53 in neurodegenerative diseases. Neurodegener Dis (2011) 0.86
Reversible aggregation of PABPN1 pre-inclusion structures. Nucleus (2011) 0.86
Structural Mechanisms of Mutant Huntingtin Aggregation Suppression by the Synthetic Chaperonin-like CCT5 Complex Explained by Cryoelectron Tomography. J Biol Chem (2015) 0.86
Elongation kinetics of polyglutamine peptide fibrils: a quartz crystal microbalance with dissipation study. J Mol Biol (2012) 0.84
Dynamic imaging by fluorescence correlation spectroscopy identifies diverse populations of polyglutamine oligomers formed in vivo. J Biol Chem (2012) 0.84
Monomeric, oligomeric and polymeric proteins in huntington disease and other diseases of polyglutamine expansion. Brain Sci (2014) 0.84
Structural formation of huntingtin exon 1 aggregates probed by small-angle neutron scattering. Biophys J (2011) 0.82
From pathways to targets: understanding the mechanisms behind polyglutamine disease. Biomed Res Int (2014) 0.81
Fragments of HdhQ150 mutant huntingtin form a soluble oligomer pool that declines with aggregate deposition upon aging. PLoS One (2012) 0.81
A native interactor scaffolds and stabilizes toxic ATAXIN-1 oligomers in SCA1. Elife (2015) 0.81
Super-resolution fluorescence of huntingtin reveals growth of globular species into short fibers and coexistence of distinct aggregates. ACS Chem Biol (2014) 0.81
Protein misfolding detected early in pathogenesis of transgenic mouse model of Huntington disease using amyloid seeding assay. J Biol Chem (2011) 0.81
Chatting with the neighbors: crosstalk between Rho-kinase (ROCK) and other signaling pathways for treatment of neurological disorders. Front Neurosci (2015) 0.81
Huntington's disease cerebrospinal fluid seeds aggregation of mutant huntingtin. Mol Psychiatry (2015) 0.80
Proteasome-mediated proteolysis of the polyglutamine-expanded androgen receptor is a late event in spinal and bulbar muscular atrophy (SBMA) pathogenesis. J Biol Chem (2015) 0.80
Identification of novel polyglutamine-expanded aggregation species in spinal and bulbar muscular atrophy. Brain Res (2015) 0.78
Delayed emergence of subdiffraction-sized mutant huntingtin fibrils following inclusion body formation. Q Rev Biophys (2015) 0.78
p62 plays a protective role in the autophagic degradation of polyglutamine protein oligomers in polyglutamine disease model flies. J Biol Chem (2014) 0.78
Polyglutamine aggregates impair lipid membrane integrity and enhance lipid membrane rigidity. Biochim Biophys Acta (2016) 0.78
Ubiquitin-activating enzyme activity contributes to differential accumulation of mutant huntingtin in brain and peripheral tissues. J Neurosci (2014) 0.78
Location trumps length: polyglutamine-mediated changes in folding and aggregation of a host protein. Biophys J (2011) 0.78
Studying polyglutamine aggregation in Caenorhabditis elegans using an analytical ultracentrifuge equipped with fluorescence detection. Protein Sci (2015) 0.77
Huntingtin fragments and SOD1 mutants form soluble oligomers in the cell. PLoS One (2012) 0.76
Making (anti-) sense out of huntingtin levels in Huntington disease. Mol Neurodegener (2015) 0.76
Investigating the structural impact of the glutamine repeat in huntingtin assembly. Biophys J (2014) 0.76
Acetylation within the First 17 Residues of Huntingtin Exon 1 Alters Aggregation and Lipid Binding. Biophys J (2016) 0.76
An Intein-based Strategy for the Production of Tag-free Huntingtin Exon 1 Proteins Enables New Insights into the Polyglutamine Dependence of Httex1 Aggregation and Fibril Formation. J Biol Chem (2016) 0.76
FUS/TLS acts as an aggregation-dependent modifier of polyglutamine disease model mice. Sci Rep (2016) 0.76
The emerging role of the first 17 amino acids of huntingtin in Huntington's disease. Biomol Concepts (2015) 0.76
Neurodegeneration caused by polyglutamine expansion is regulated by P-glycoprotein in Drosophila melanogaster. Genetics (2013) 0.76
Aggregation landscapes of Huntingtin exon 1 protein fragments and the critical repeat length for the onset of Huntington's disease. Proc Natl Acad Sci U S A (2017) 0.75
An Intrabody Drug (rAAV6-INT41) Reduces the Binding of N-Terminal Huntingtin Fragment(s) to DNA to Basal Levels in PC12 Cells and Delays Cognitive Loss in the R6/2 Animal Model. J Neurodegener Dis (2016) 0.75
Conformational properties of polyglutamine sequences in guanidine hydrochloride solutions. Biophys J (2012) 0.75
Sedimentation Velocity Analysis With Fluorescence Detection of Mutant Huntingtin Exon 1 Aggregation in Drosophila Melanogaster and Caenorhabditis Elegans. Biochemistry (2017) 0.75
Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell (1996) 12.59
Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature (2004) 11.82
Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science (1997) 11.53
Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell (1997) 9.57
Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell (1997) 7.59
Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell (1998) 7.13
Glutamine repeats and neurodegeneration. Annu Rev Neurosci (2000) 6.06
Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat Genet (1993) 5.70
Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. Proc Natl Acad Sci U S A (1999) 4.58
Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci (1999) 4.27
CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol (1997) 4.01
SUMO modification of Huntingtin and Huntington's disease pathology. Science (2004) 3.85
Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation. Proc Natl Acad Sci U S A (2002) 3.56
Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc Natl Acad Sci U S A (2000) 3.43
Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. Proc Natl Acad Sci U S A (1999) 3.33
Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron (2002) 3.15
Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature (1995) 2.92
Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. J Mol Biol (2001) 2.80
Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism. Nat Struct Mol Biol (2009) 2.77
Amyloid-like features of polyglutamine aggregates and their assembly kinetics. Biochemistry (2002) 2.59
Flanking sequences profoundly alter polyglutamine toxicity in yeast. Proc Natl Acad Sci U S A (2006) 2.59
Hsp70 and Hsp40 attenuate formation of spherical and annular polyglutamine oligomers by partitioning monomer. Nat Struct Mol Biol (2004) 2.50
A toxic monomeric conformer of the polyglutamine protein. Nat Struct Mol Biol (2007) 2.33
In situ atomic force microscopy study of Alzheimer's beta-amyloid peptide on different substrates: new insights into mechanism of beta-sheet formation. Proc Natl Acad Sci U S A (1999) 2.24
Oligoproline effects on polyglutamine conformation and aggregation. J Mol Biol (2005) 2.14
Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization. J Biol Chem (2002) 2.12
New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins. Brain Res Bull (2001) 2.03
Secondary structure of Huntingtin amino-terminal region. Structure (2009) 1.98
Distinct conformations of in vitro and in vivo amyloids of huntingtin-exon1 show different cytotoxicity. Proc Natl Acad Sci U S A (2009) 1.96
Mutational analysis of the structural organization of polyglutamine aggregates. Proc Natl Acad Sci U S A (2002) 1.89
The influence of huntingtin protein size on nuclear localization and cellular toxicity. J Cell Biol (1998) 1.87
A cellular model that recapitulates major pathogenic steps of Huntington's disease. Hum Mol Genet (1998) 1.87
A network of protein interactions determines polyglutamine toxicity. Proc Natl Acad Sci U S A (2006) 1.85
Huntington's disease: the challenge for cell biologists. Trends Cell Biol (2000) 1.80
Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease. J Neurosci (2009) 1.73
Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic. Hum Mol Genet (2007) 1.66
Flanking polyproline sequences inhibit beta-sheet structure in polyglutamine segments by inducing PPII-like helix structure. J Mol Biol (2007) 1.59
polyglutamine aggregation nucleation: thermodynamics of a highly unfavorable protein folding reaction. Proc Natl Acad Sci U S A (2005) 1.57
Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease. J Neurochem (2007) 1.54
Mutant huntingtin N-terminal fragments of specific size mediate aggregation and toxicity in neuronal cells. J Biol Chem (2009) 1.47
In-situ atomic force microscopy study of beta-amyloid fibrillization. J Mol Biol (2000) 1.40
Monoclonal antibodies recognize distinct conformational epitopes formed by polyglutamine in a mutant huntingtin fragment. J Biol Chem (2009) 1.37
Extended polyglutamine tracts cause aggregation and structural perturbation of an adjacent beta barrel protein. J Biol Chem (2006) 1.37
Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. J Neurosci (2004) 1.27
Requirement of an intact microtubule cytoskeleton for aggregation and inclusion body formation by a mutant huntingtin fragment. Proc Natl Acad Sci U S A (2002) 1.24
Endocytosis machinery is involved in aggregation of proteins with expanded polyglutamine domains. FASEB J (2007) 1.22
Polyglutamines placed into context. Neuron (2003) 1.21
Alterations in N-methyl-D-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease. J Neurosci Res (2005) 1.15
The interplay between PolyQ and protein context delays aggregation by forming a reservoir of protofibrils. PLoS One (2006) 1.15
Amino acid sequences flanking polyglutamine stretches influence their potential for aggregate formation. Neuroreport (2001) 1.10
Intra- and intermolecular beta-pleated sheet formation in glutamine-repeat inserted myoglobin as a model for polyglutamine diseases. J Biol Chem (2001) 1.02
Detection of polyglutamine protein oligomers in cells by fluorescence correlation spectroscopy. J Biol Chem (2007) 0.98
Expansion of amino acid homo-sequences in proteins: insights into the role of amino acid homo-polymers and of the protein context in aggregation. Cell Mol Life Sci (2006) 0.97
In situ AFM studies of astrocyte-secreted apolipoprotein E- and J-containing lipoproteins. J Colloid Interface Sci (2004) 0.92
Sodium dodecyl sulfate-insoluble oligomers are involved in polyglutamine degeneration. FASEB J (2008) 0.85
Polyglutamine dances the conformational cha-cha-cha. Structure (2009) 0.80
Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A (2003) 4.44
Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov (2008) 4.43
Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci U S A (2004) 3.73
Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell (2011) 3.28
Autophagy and its possible roles in nervous system diseases, damage and repair. Autophagy (2005) 3.27
Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem (2007) 3.13
Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci (2012) 3.11
Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein. Science (2003) 2.89
Altered parvalbumin-positive neuron distribution in basal ganglia of individuals with Tourette syndrome. Proc Natl Acad Sci U S A (2005) 2.72
Flanking sequences profoundly alter polyglutamine toxicity in yeast. Proc Natl Acad Sci U S A (2006) 2.59
Hsp70 and Hsp40 attenuate formation of spherical and annular polyglutamine oligomers by partitioning monomer. Nat Struct Mol Biol (2004) 2.50
A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat Genet (2005) 2.28
Identifying polyglutamine protein species in situ that best predict neurodegeneration. Nat Chem Biol (2011) 2.24
Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr Biol (2009) 2.19
The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease. Curr Biol (2011) 2.17
SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc Natl Acad Sci U S A (2010) 2.09
Autophagy regulates the processing of amino terminal huntingtin fragments. Hum Mol Genet (2003) 2.08
A network of protein interactions determines polyglutamine toxicity. Proc Natl Acad Sci U S A (2006) 1.85
Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. Hum Mol Genet (2006) 1.77
Identical oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse models of Huntington's disease. Hum Mol Genet (2010) 1.71
Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J Biol Chem (2001) 1.70
Single-step detection of mutant huntingtin in animal and human tissues: a bioassay for Huntington's disease. Anal Biochem (2009) 1.64
Chaperone functions of the E3 ubiquitin ligase CHIP. J Biol Chem (2007) 1.63
Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. Proc Natl Acad Sci U S A (2005) 1.52
Monoclonal antibodies recognize distinct conformational epitopes formed by polyglutamine in a mutant huntingtin fragment. J Biol Chem (2009) 1.37
Striatal potassium channel dysfunction in Huntington's disease transgenic mice. J Neurophysiol (2004) 1.30
Induction of the phase II detoxification pathway suppresses neuron loss in Drosophila models of Parkinson's disease. J Neurosci (2008) 1.28
Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease. EMBO Mol Med (2010) 1.27
Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. J Neurosci (2004) 1.27
A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila. Nat Genet (2002) 1.25
Elevated NADPH oxidase activity contributes to oxidative stress and cell death in Huntington's disease. Hum Mol Genet (2012) 1.25
Loss of Hsp70 exacerbates pathogenesis but not levels of fibrillar aggregates in a mouse model of Huntington's disease. J Neurosci (2009) 1.24
Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease. Neurobiol Dis (2012) 1.23
Aberrant Rab11-dependent trafficking of the neuronal glutamate transporter EAAC1 causes oxidative stress and cell death in Huntington's disease. J Neurosci (2010) 1.23
Huntingtin associates with acidic phospholipids at the plasma membrane. J Biol Chem (2005) 1.22
Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease. Prog Neurobiol (2009) 1.18
Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington's disease. CNS Neurol Disord Drug Targets (2010) 1.16
TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in huntington's disease. Chem Biol (2012) 1.13
Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment. J Biol Chem (2007) 1.11
Mutant huntingtin impairs immune cell migration in Huntington disease. J Clin Invest (2012) 1.11
Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease. Hum Mol Genet (2002) 1.09
Lysosomal proteases are involved in generation of N-terminal huntingtin fragments. Neurobiol Dis (2006) 1.08
Identification of novel potentially toxic oligomers formed in vitro from mammalian-derived expanded huntingtin exon-1 protein. J Biol Chem (2012) 1.07
Disease-modifying pathways in neurodegeneration. J Neurosci (2006) 1.06
Mutant huntingtin impairs vesicle formation from recycling endosomes by interfering with Rab11 activity. Mol Cell Biol (2009) 1.05
Bone marrow transplantation confers modest benefits in mouse models of Huntington's disease. J Neurosci (2012) 1.03
Polyglutamine expansion in huntingtin alters its interaction with phospholipids. J Neurochem (2009) 1.03
Mutant huntingtin and glycogen synthase kinase 3-beta accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington's disease. J Neurosci Res (2010) 1.02
Hsp70 and Hsp40 functionally interact with soluble mutant huntingtin oligomers in a classic ATP-dependent reaction cycle. J Biol Chem (2010) 1.01
Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease. J Neurosci (2012) 1.00
Severe ultrastructural mitochondrial changes in lymphoblasts homozygous for Huntington disease mutation. Mech Ageing Dev (2005) 1.00
The role of chaperone-mediated autophagy in huntingtin degradation. PLoS One (2012) 0.99
Targeting H3K4 trimethylation in Huntington disease. Proc Natl Acad Sci U S A (2013) 0.98
A function of huntingtin in guanine nucleotide exchange on Rab11. Neuroreport (2008) 0.97
Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation. Neurobiol Dis (2003) 0.97
Fly models of Huntington's disease. Hum Mol Genet (2003) 0.97
Distribution and ultrastructural localization of torsinA immunoreactivity in the human brain. Brain Res (2003) 0.95
Disruption of Rab11 activity in a knock-in mouse model of Huntington's disease. Neurobiol Dis (2009) 0.95
Functional gene expression profiling in yeast implicates translational dysfunction in mutant huntingtin toxicity. J Biol Chem (2010) 0.94
Expanded polyglutamine-binding peptoid as a novel therapeutic agent for treatment of Huntington's disease. Chem Biol (2011) 0.94
Cysteine oxidation within N-terminal mutant huntingtin promotes oligomerization and delays clearance of soluble protein. J Biol Chem (2011) 0.93
Exogenous delivery of chaperonin subunit fragment ApiCCT1 modulates mutant Huntingtin cellular phenotypes. Proc Natl Acad Sci U S A (2013) 0.93
Targeted deletion of kynurenine 3-monooxygenase in mice: a new tool for studying kynurenine pathway metabolism in periphery and brain. J Biol Chem (2013) 0.93
Arfaptin 2 regulates the aggregation of mutant huntingtin protein. Nat Cell Biol (2002) 0.93
Connecting the dots in Huntington's disease with protein interaction networks. Genome Biol (2005) 0.92
The recycling endosome and its role in neurological disorders. Prog Neurobiol (2011) 0.92
Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models. J Neurosci (2012) 0.92
Drosophila eye color mutants as therapeutic tools for Huntington disease. Fly (Austin) (2012) 0.91
Screening for genetic modifiers of amyloid toxicity in yeast. Methods Enzymol (2006) 0.91
Huntingtin-lowering strategies in Huntington's disease: antisense oligonucleotides, small RNAs, and gene editing. Mov Disord (2014) 0.90
Novel one-step immunoassays to quantify α-synuclein: applications for biomarker development and high-throughput screening. J Biol Chem (2012) 0.90
Multiple phenotypes in Huntington disease mouse neural stem cells. Mol Cell Neurosci (2012) 0.89
Detection of Mutant Huntingtin Aggregation Conformers and Modulation of SDS-Soluble Fibrillar Oligomers by Small Molecules. J Huntingtons Dis (2012) 0.89
SUMO-2 and PIAS1 modulate insoluble mutant huntingtin protein accumulation. Cell Rep (2013) 0.88
Cysteine string protein (CSP) inhibition of N-type calcium channels is blocked by mutant huntingtin. J Biol Chem (2003) 0.87
Functional similarities between the small heat shock proteins Mycobacterium tuberculosis HSP 16.3 and human alphaB-crystallin. Eur J Biochem (2002) 0.87
Molecular genetics approaches in yeast to study amyloid diseases. J Mol Neurosci (2004) 0.85
Reagents that block neuronal death from Huntington's disease also curb oxidative stress. Neuroreport (2012) 0.85